JP5503096B2 - 感受性哺乳動物において気道疾患を引き起こすウイルス - Google Patents

感受性哺乳動物において気道疾患を引き起こすウイルス Download PDF

Info

Publication number
JP5503096B2
JP5503096B2 JP2002557978A JP2002557978A JP5503096B2 JP 5503096 B2 JP5503096 B2 JP 5503096B2 JP 2002557978 A JP2002557978 A JP 2002557978A JP 2002557978 A JP2002557978 A JP 2002557978A JP 5503096 B2 JP5503096 B2 JP 5503096B2
Authority
JP
Japan
Prior art keywords
protein
amino acid
acid sequence
mpv
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002557978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531220A (ja
JP2004531220A5 (enExample
Inventor
ジョン，ジャン，コルネリウス デ
フォッチャー，ロナルダス，アドリアナス，マリア
デン フーゲン，ベルナデッタ，ゲラルダ ヴァン
オステルハウス，アルベルタス，ドミニクス，マルセリナス，エラスムス
グルーン，ジャン
Original Assignee
ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5503096(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ filed Critical ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ
Publication of JP2004531220A publication Critical patent/JP2004531220A/ja
Publication of JP2004531220A5 publication Critical patent/JP2004531220A5/ja
Application granted granted Critical
Publication of JP5503096B2 publication Critical patent/JP5503096B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18341—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2002557978A 2001-01-19 2002-01-18 感受性哺乳動物において気道疾患を引き起こすウイルス Expired - Lifetime JP5503096B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01200213 2001-01-19
EP01200213.5 2001-01-19
EP01203985.5 2001-10-18
EP01203985 2001-10-18
PCT/NL2002/000040 WO2002057302A2 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011050982A Division JP2011177173A (ja) 2001-01-19 2011-03-09 感受性哺乳動物において気道疾患を引き起こすウイルス

Publications (3)

Publication Number Publication Date
JP2004531220A JP2004531220A (ja) 2004-10-14
JP2004531220A5 JP2004531220A5 (enExample) 2005-12-22
JP5503096B2 true JP5503096B2 (ja) 2014-05-28

Family

ID=26076820

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002557978A Expired - Lifetime JP5503096B2 (ja) 2001-01-19 2002-01-18 感受性哺乳動物において気道疾患を引き起こすウイルス
JP2011050982A Pending JP2011177173A (ja) 2001-01-19 2011-03-09 感受性哺乳動物において気道疾患を引き起こすウイルス
JP2013142224A Expired - Lifetime JP5813060B2 (ja) 2001-01-19 2013-07-08 感受性哺乳動物において気道疾患を引き起こすウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011050982A Pending JP2011177173A (ja) 2001-01-19 2011-03-09 感受性哺乳動物において気道疾患を引き起こすウイルス
JP2013142224A Expired - Lifetime JP5813060B2 (ja) 2001-01-19 2013-07-08 感受性哺乳動物において気道疾患を引き起こすウイルス

Country Status (21)

Country Link
US (10) US8927206B2 (enExample)
EP (1) EP1351981B1 (enExample)
JP (3) JP5503096B2 (enExample)
KR (4) KR20040002853A (enExample)
CN (2) CN1524088B (enExample)
AU (1) AU2002228471B2 (enExample)
BR (1) BR0206591A (enExample)
CA (1) CA2435180C (enExample)
DK (1) DK1351981T3 (enExample)
EA (1) EA006879B1 (enExample)
ES (1) ES2393468T3 (enExample)
HU (1) HUP0500244A3 (enExample)
IL (1) IL157003A0 (enExample)
MX (1) MXPA03006430A (enExample)
NO (1) NO335551B1 (enExample)
NZ (2) NZ555567A (enExample)
PL (1) PL213926B1 (enExample)
SG (1) SG149684A1 (enExample)
UA (1) UA93981C2 (enExample)
WO (1) WO2002057302A2 (enExample)
ZA (1) ZA200305655B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334543B2 (en) 2001-01-19 2016-05-10 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US11220718B2 (en) 2002-02-21 2022-01-11 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094105A1 (en) 1998-04-24 2006-05-04 University Hospitals Of Cleveland Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2003297602A1 (en) * 2002-12-02 2004-06-23 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
AU2003294533A1 (en) * 2002-12-19 2004-07-14 Universite Laval Molecular methods and compositions for detecting and quantifying respiratory viruses
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
US7547512B2 (en) 2003-03-24 2009-06-16 The University Of Hong Kong High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
AU2004226369A1 (en) * 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US7704720B2 (en) * 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
JP2006524511A (ja) * 2003-04-25 2006-11-02 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
EP1473037A1 (en) * 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
AU2004274717A1 (en) * 2003-09-22 2005-03-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A method for detecting Nipah virus and method for providing immunoprotection against henipaviruses
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
JP4546212B2 (ja) * 2004-10-21 2010-09-15 三菱化学メディエンス株式会社 抗原蛋白質を発現した細胞を利用する抗体測定方法
AU2006223138B2 (en) * 2005-03-10 2012-04-05 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20080175836A1 (en) * 2005-12-09 2008-07-24 Karp Nelson M Immunogenic composition based on conditionally live virion and method for producing the same
US8492097B2 (en) 2006-04-24 2013-07-23 Diagnostic Hybrids, Inc. Compositions and methods for human metapneumovirus monoclonal antibodies
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
EP3351628B1 (en) 2008-10-24 2023-07-26 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
KR101073991B1 (ko) * 2009-10-27 2011-10-21 대한민국 국내사육 닭에서 유행하는 신규한 ｂ형 조류메타뉴모바이러스 ｓｃ1509주 및 이의 용도
CN101880732B (zh) * 2010-06-29 2012-10-10 中国药品生物制品检定所 猴副流感病毒5型的rt-pcr检测方法及试剂盒
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
PL2828293T3 (pl) 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EA039682B1 (ru) * 2012-06-04 2022-02-28 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
CN102676701B (zh) * 2012-06-11 2013-08-14 广东温氏食品集团股份有限公司 禽肺病毒通用型rt-pcr检测引物及检测方法
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN103360472B (zh) * 2013-07-30 2015-02-25 北京市农林科学院 禽偏肺病毒抗体elisa检测试剂盒
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015135925A1 (en) * 2014-03-10 2015-09-17 Fondation The Ark Respiratory syncytial virus (rsv) replication inhibitors
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
DE102016215118A1 (de) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infektiöse Bronchitis (IB)-Virus Varianten und diesbezügliche Zusammensetzungen, Verwendungen und Verfahren
EP3383428B1 (en) * 2016-10-31 2022-02-09 Wuhan Sanli Biotechnology Co., Ltd. Respiratory syncytial virus vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
TWI848944B (zh) * 2018-04-23 2024-07-21 美國衛生與公眾服務部 嵌合載體
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20240279610A1 (en) 2021-06-09 2024-08-22 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
WO2023004307A1 (en) * 2021-07-19 2023-01-26 Epivax, Inc. T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989010405A1 (en) 1988-04-22 1989-11-02 The Upjohn Company Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
ES2129199T3 (es) 1994-04-19 1999-06-01 Sanquin Bloedvoorziening Procedimientos de discriminacion entre las variantes del virus de la inmunodeficiencia humana que inducen el sincitio y los que no inducen el sincitio y cebadores para la utilizacion en los procedimientos.
SE504386C2 (sv) 1994-05-30 1997-01-27 Bengt Wilhelm Toernqvist Bottenkonstruktion på ett deplacementfartygsskrov
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
ES2109189B1 (es) 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
EP0932684A2 (en) 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
US5817494A (en) 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
JP4434478B2 (ja) 1997-07-11 2010-03-17 イエール ユニバーシティー リエンジニアリングされた外被を有するラブドウイルス
CA2302867A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU6200399A (en) * 1998-10-05 2000-04-26 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
EP1186667B1 (en) 1999-05-18 2007-07-18 Dnavec Research Inc. Envelope gene-deficient virus vector of paramyxoviridae
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
CZ296735B6 (cs) 1999-07-29 2006-06-14 Hatebur Umformmaschinen Ag Zarízení k vytvárení zvedacího a spoustecího pohybu
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CN102766605A (zh) 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6387586B1 (en) 2000-11-06 2002-05-14 Eastman Kodak Company High contrast visually adaptive radiographic film and imaging assembly for thoracic imaging
CA2430115C (en) 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US7704509B2 (en) * 2001-11-21 2010-04-27 United States Of America Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP4553589B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
DE10221836A1 (de) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US6605283B1 (en) * 2002-11-01 2003-08-12 The United States Of America As Represented By The Secretary Of Agriculture Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene
AU2003294533A1 (en) 2002-12-19 2004-07-14 Universite Laval Molecular methods and compositions for detecting and quantifying respiratory viruses
US7704491B2 (en) * 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP1602103A1 (en) 2003-03-05 2005-12-07 Koninklijke Philips Electronics N.V. Apparatus and method of determining a power parameter for writing/erasing information on an optical medium.
EP1613650A2 (en) 2003-04-08 2006-01-11 CoroNovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
JP2006524511A (ja) 2003-04-25 2006-11-02 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
US7704720B2 (en) * 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
EP1533370A1 (en) 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
EP1548748A1 (en) 2003-12-17 2005-06-29 Interuniversitaire Microelectronica Centrum vzw ( IMEC) A method for making probes for atomic force microscopy
WO2005080991A1 (en) 2004-02-20 2005-09-01 Erasmus Universiteit Rotterdam Method to detect antigen-specific cytolytic activity
US8318423B2 (en) 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
WO2006051069A2 (en) 2004-11-11 2006-05-18 Solvay Pharmaceuticals B.V. Defective influenza virus particles
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
AU2006223138B2 (en) * 2005-03-10 2012-04-05 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
EP1748447B1 (en) 2005-07-28 2008-10-22 Interuniversitair Microelektronica Centrum ( Imec) Dual tip atomic force microscopy probe and method for producing such a probe
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US20090186050A1 (en) 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US10485863B2 (en) 2010-07-23 2019-11-26 Novavax AB Influenza vaccine
JP5923723B2 (ja) 2011-06-02 2016-05-25 パナソニックＩｐマネジメント株式会社 人物属性推定システム、人物属性推定装置、及び人物属性推定方法
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
CN109402065B (zh) * 2018-08-08 2021-07-30 温氏食品集团股份有限公司 一种番鸭c亚型禽偏肺病毒弱毒株及其制备和应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334543B2 (en) 2001-01-19 2016-05-10 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US9376726B2 (en) 2001-01-19 2016-06-28 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
US9593386B2 (en) 2001-01-19 2017-03-14 Erasmus Universiteit Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US10519517B2 (en) 2001-01-19 2019-12-31 Vironovative Bv Virus causing respiratory tract illness in susceptible mammals
US11162148B2 (en) 2001-01-19 2021-11-02 Erasmus University Medical Center Rotterdam Virus causing respiratory tract illness in susceptible mammals
US11220718B2 (en) 2002-02-21 2022-01-11 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Also Published As

Publication number Publication date
NO20033272D0 (no) 2003-07-18
EA200300810A1 (ru) 2003-12-25
EP1351981B1 (en) 2012-08-08
US20200140964A1 (en) 2020-05-07
CN1524088B (zh) 2012-11-07
JP2011177173A (ja) 2011-09-15
US9376726B2 (en) 2016-06-28
WO2002057302A8 (en) 2003-11-13
CA2435180A1 (en) 2002-07-25
US7531342B2 (en) 2009-05-12
US20170183747A1 (en) 2017-06-29
UA93981C2 (ru) 2011-03-25
EA006879B1 (ru) 2006-04-28
US20100143407A1 (en) 2010-06-10
PL367826A1 (en) 2005-03-07
CN101921732A (zh) 2010-12-22
US20140295409A1 (en) 2014-10-02
PL213926B1 (pl) 2013-05-31
SG149684A1 (en) 2009-02-27
KR20100034059A (ko) 2010-03-31
KR101105984B1 (ko) 2012-01-18
HK1068898A1 (en) 2005-05-06
US20190119762A1 (en) 2019-04-25
US9334543B2 (en) 2016-05-10
WO2002057302A3 (en) 2002-12-27
KR100964413B1 (ko) 2010-06-15
WO2002057302A2 (en) 2002-07-25
KR20040002853A (ko) 2004-01-07
ES2393468T3 (es) 2012-12-21
US10519517B2 (en) 2019-12-31
CA2435180C (en) 2019-04-09
KR20090006236A (ko) 2009-01-14
US9593386B2 (en) 2017-03-14
NO335551B1 (no) 2014-12-29
NZ527221A (en) 2006-09-29
ZA200305655B (en) 2004-07-22
KR101412317B1 (ko) 2014-07-24
US8927206B2 (en) 2015-01-06
HUP0500244A3 (en) 2011-03-28
US20040005544A1 (en) 2004-01-08
HUP0500244A2 (hu) 2005-05-30
NZ555567A (en) 2008-07-31
JP5813060B2 (ja) 2015-11-17
US20050118195A1 (en) 2005-06-02
US20150093746A1 (en) 2015-04-02
CN1524088A (zh) 2004-08-25
US11162148B2 (en) 2021-11-02
US20160244850A1 (en) 2016-08-25
KR20110113658A (ko) 2011-10-17
MXPA03006430A (es) 2004-10-15
EP1351981A2 (en) 2003-10-15
IL157003A0 (en) 2004-02-08
JP2004531220A (ja) 2004-10-14
AU2002228471B2 (en) 2008-02-14
NO20033272L (no) 2003-09-18
JP2014027930A (ja) 2014-02-13
US20180057893A1 (en) 2018-03-01
US10167524B2 (en) 2019-01-01
US9803252B2 (en) 2017-10-31
US8722341B2 (en) 2014-05-13
BR0206591A (pt) 2005-02-01
DK1351981T3 (da) 2012-11-26

Similar Documents

Publication Publication Date Title
JP5813060B2 (ja) 感受性哺乳動物において気道疾患を引き起こすウイルス
TWI405851B (zh) 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用
AU2002228471A1 (en) A virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) Virus causing respiratory tract illness in susceptible mammals
AU2008202111B2 (en) A virus causing respiratory tract illness in susceptible mammals
HK1068898B (en) A virus causing respiratory tract illness in susceptible mammals
HK1151831A (en) A virus causing respiratory tract illness in susceptible mammals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110519

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140314

R150 Certificate of patent or registration of utility model

Ref document number: 5503096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term